Pharmaceuticals November 18, 2024

Tirzepatide’s Prediabetes Triumph November 18, 2024

Eli Lilly’s GLP-1 tirzepatide has triumphed yet again, as the full SURMOUNT-1 trial showed that the drug kept nearly 99% of prediabetic patients diabetes-free over 3 years, while improving cardiometabolic metrics. In the final results from the three-year SURMOUNT-1 trial, tirzepatide lowered the risk of progression to Type 2 diabetes by 94% versus placebo in […]

Surgeries & Interventions November 14, 2024

Forgotten IVC Filters Aren’t SAFE November 14, 2024

Troubling results from the SAFE-IVC study revealed that just one in six patients gets their inferior vena cava filters removed, despite clear guidelines calling for IVC filter removal as early as possible. Out of SAFE-IVC’s roughly 270k Medicare beneficiaries, only 15% had their IVC filters retrieved within 1.2 years of insertion. Patients who didn’t have […]

Surgeries & Interventions November 11, 2024

LimFlow Limits Limb-Threatening Ischemia November 11, 2024

Late-breaking second year results from the PROMISE II trial showed that the LimFlow system achieved strong outcomes for avoiding amputations and promoting limb salvage among “no-option” patients with chronic limb-threatening ischemia (CLTI).  LimFlow remained effective at two years, with a 65% limb salvage rate that was just 4% below the PROMISE II trial’s one year […]

Atrial Fibrillation November 7, 2024

Boston Scientific Bolsters AFib Mapping with Cortex Acquisition November 7, 2024

Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. for an undisclosed sum. Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases. […]

More Stories

Surgeries & Interventions November 4, 2024

TCT 2024’s Top TAVR Studies November 4, 2024

This year’s TCT conference saw a deluge of TAVR studies examining everything from the efficacy of valve designs to TAVR’s impact on aortic and tricuspid regurgitation. Out of all these TAVR studies, the four that could have the greatest clinical impact focused on interventional timing and the risk of comorbidities and procedural complications. The EARLY […]

Cardiology October 31, 2024

The 40 Best Cardiology Newsletters, Websites, and Influencers to Follow in 2024 October 31, 2024

We’re dedicating today’s top story to the people and publications that we rely on to find the most interesting cardiology stories from across the web. Assuming that you already subscribe to Cardiac Wire, these are the 40 other newsletters, websites, and social media stars to follow if you want to keep up with the latest […]

Cardiovascular Disease October 28, 2024

America’s Growing CVD Problem October 28, 2024

It’s well known that heart disease is the U.S.’s top cause of death, and our rising CVD rates have been widely covered, but a look back on some of the biggest stories of 2024 suggests that cardiovascular disease is about to become a much bigger problem. The Takeaway These truly frightening statistics suggest that the […]

Cardiology October 24, 2024

The State of Cardiology Employment October 24, 2024

MedAxiom released its 12th annual Cardiovascular Provider Compensation and Production Report, providing an in-depth look at the current state of working in cardiology. The massive 60-page report (n=5,663 providers, 202 programs, 2023 data) outlined four notable employment trends… Rising PE Ownership – Nearly 50% of surveyed private practice groups were also part of a private […]

Pharmaceuticals October 21, 2024

Exploring Semaglutide’s Cardiovascular Impact October 21, 2024

JACC took a deep dive into semaglutide’s cardiovascular impact, publishing six analyses of three separate trials that delivered new insights into the drug’s heart benefits, while raising even more questions about how it works. One STEP-HFpEF trial analysis showed that patients with obesity-related HFpEF on semaglutide achieved cardiac remodeling benefits beyond the impact of weight […]

Atrial Fibrillation October 17, 2024

InCarda Gets Mixed Results in AFib Inhaler Trial October 17, 2024

AFib inhalers took a small step closer to becoming a reality after InCarda Therapeutics’ Phase 3 RESTORE-1 trial showed that its FlecIH-103 inhaled flecainide formulation can rapidly convert paroxysmal AFib to normal sinus rhythm. However, challenges with the study suggest that InCarda has more work to do in order to achieve this reality. The new […]

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!